Close

Incyte (INCY) Tops Q2 EPS by 5c

August 3, 2021 7:22 AM EDT

Incyte (NASDAQ: INCY) reported Q2 EPS of $0.80, $0.05 better than the analyst estimate of $0.75. Revenue for the quarter came in at $705.7 million versus the consensus estimate of $686.98 million.

Guidance:

Current

Previous

Jakafi net product revenues

$2,125 - $2,170 million

$2,125 - $2,200 million

Other Hematology/Oncology net product revenues

$155 - $170 million

$145 - $160 million

GAAP Cost of product revenues

6 – 7% of net product revenues

Unchanged

Non-GAAP Cost of product revenues1

5 – 6% of net product revenues

Unchanged

GAAP Research and development expenses

$1,350 - $1,390 million

Unchanged

Non-GAAP Research and development expenses2

$1,220 - $1,250 million

Unchanged

GAAP Selling, general and administrative expenses

$725 - $755 million

$735 - $775 million

Non-GAAP Selling, general and administrative expenses3

$655 - $680 million

$665 - $700 million

For earnings history and earnings-related data on Incyte (INCY) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings